Search This Blog

Friday, May 10, 2024

Weak Sales From Lipitor, Norvasc Hurt Viatris' Q1 Earnings, Lowers Annual Forecast

 

  • Viatris expects adjusted EBITDA and EPS to be slightly higher in the second half vs. the first half 2024.
  • The company expects the 2024 adjusted gross margin to be moderate in the second half due to segment and product mix.

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)